Development
Cytokinetics, Incorporated
CYTK
$35.14
-$1.02-2.82%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -526.24M | -526.73M | -539.62M | -430.80M | -388.96M |
| Total Depreciation and Amortization | 11.89M | 7.22M | 6.77M | 6.32M | 5.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.93M | 105.98M | 121.23M | 113.86M | 108.33M |
| Change in Net Operating Assets | 3.09M | -24.95M | -14.70M | -84.37M | -24.70M |
| Cash from Operations | -414.33M | -438.49M | -426.32M | -394.99M | -299.52M |
| Capital Expenditure | -1.42M | -4.54M | -10.66M | -10.80M | -11.34M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 240.67M | 354.46M | -4.84M | -21.56M | -250.80M |
| Cash from Investing | 239.25M | 349.91M | -15.50M | -32.36M | -262.13M |
| Total Debt Issued | -- | 0.00 | 523.59M | 523.59M | 523.59M |
| Total Debt Repaid | -858.00K | -741.00K | -141.28M | -141.33M | -188.93M |
| Issuance of Common Stock | 182.69M | 17.27M | 19.02M | 17.02M | 17.54M |
| Repurchase of Common Stock | -10.52M | -10.52M | -10.52M | -10.52M | -9.60M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 50.00M | 76.39M | 26.39M | 26.39M | 173.56M |
| Cash from Financing | 221.32M | 82.40M | 417.20M | 415.14M | 516.17M |
| Foreign Exchange rate Adjustments | -20.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.22M | -6.17M | -24.62M | -12.21M | -45.48M |